3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
12
Tumor-Agnostic
6
Gastrointestinal
4
Genitourinary
2
Breast
2
Sarcoma
1
Other solid neoplasm
1
Other hematologic neoplasm
1
NET
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Endocrine
1
Dermatologic
1
CNS
1
Conditions
Thyroid Neoplasms
1
Thyroid Cancer, Papillary
1
Thoracic Neoplasms
1
Sarcoma
1
Salivary Gland Neoplasms
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroendocrine Tumors
1
Neoplasms by Site
1
Neoplasms
1
Melanoma
1
Lymphoma, Large-Cell, Anaplastic
1
Intestinal Neoplasms
1
Intestinal Diseases
1
Head and Neck Neoplasms
1
Gastrointestinal Neoplasms
1
Gastrointestinal Diseases
1
Digestive System Neoplasms
1
Digestive System Diseases
1
Colorectal Neoplasms
1
Colonic Diseases
1
Cholangiocarcinoma
1
Carcinoma, Renal Cell
1
Carcinoma, Bronchogenic
1
Bronchial Neoplasms
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
Cisplatin
315
Radiotherapy
139
Cetuximab
133
pembrolizumab
131
Docetaxel
122
Carboplatin
119
Radiotherapy, Intensity-Modulated
97
Fluorouracil
94
Paclitaxel
92
Nivolumab
64
Gemcitabine
50
toripalimab
46
Radiation
44
Drug Therapy
39
Capecitabine
39
Magnetic Resonance Spectroscopy
38
Surgical Procedures, Operative
33
camrelizumab
31
130-nm albumin-bound paclitaxel
29
apatinib
27
tislelizumab
26
Chemoradiotherapy
26
Specimen Handling
25
Bevacizumab
24
durvalumab
23
Albumin-Bound Paclitaxel
23
nimotuzumab
22
lenvatinib
21
Sorafenib
21
Platinum
21
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
alectinib
×
Head & Neck
×
Clear all
NCT04644315
2023-08-07
ALpha-T
Hoffmann-La Roche
Phase 2
Terminated
1 enrolled
5 charts